Stocksigma LogoStocksigma Logo

Gland Pharma Approves $21M US Investment and Board Reconstitution

Gland Pharma approved a USD 21m cash investment in wholly-owned subsidiary Gland Pharma USA Inc. to subscribe to a 60% stake in newly incorporated

Gland Pharma Approves $21M US Investment and Board Reconstitution

Gland Pharma Ltd 路 Others (Uncategorized) 路 01 Oct 2026, 9:15 pm

Gland Pharma Approves $21M US Investment and Board Reconstitution Gland Pharma approved a USD 21m cash investment in wholly-owned subsidiary Gland Pharma USA Inc. to subscribe to a 60% stake in newly incorporated Novelstar Pharma Inc. by 31st Oct'26, expanding its US footprint alongside Fosun Pharma USA Inc. (40% stake). Post-transaction, Novelstar will become a step-down subsidiary with USD 35m in share capital. Additionally, effective 1st Oct'26, Wenjie Zhang resigned as Non-Executive Director, and Xingli Wang was appointed as Additional Non-Executive Director, prompting reconstitutions across key board committees.

Original exchange filing (PDF)

More announcements from Gland Pharma Ltd

All Gland Pharma Ltd announcements